🇺🇸 FDA
Pipeline program

Ledipasvir 90mg/Sofosbuvir 400 mg

GILEAD IN-US-337-4109

Approved small_molecule terminated

Quick answer

Ledipasvir 90mg/Sofosbuvir 400 mg for Hepatocellular Carcinoma is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Hepatocellular Carcinoma
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials